Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 7:57 AM ET

Biotechnology

Company Overview of LFB S.A.

Company Overview

LFB S.A., a biopharmaceutical company, develops, manufactures, and markets medicinal products for the treatment of serious and rare diseases in the therapeutic areas of immunology, haemostasis, and intensive care worldwide. Its products include plasma-derived, recombinant, and cell therapy medicinal products. The company offers therapeutic solutions to treat primary immuno-deficiency, autoimmune diseases, and acquired troubles, such as secondary immuno-deficiency; and constitutional bleeding disorders, as well as biomedicines to treat patients who are often in a critical condition due to severe deficiencies in essential plasma proteins. It is also involved in the services and intermediate bi...

3, Avenue des Tropiques

B.P. 305

Courtabœuf Cedex

Les Ulis,  91958

France

Founded in 1994

2,016 Employees

Phone:

33 1 69 82 70 10

Fax:

33 1 69 07 19 03

Key Executives for LFB S.A.

Chairman, Chief Executive Officer, Chairman of LFB Biotechnologies and Chief Executive Officer of LFB Biomedicaments
Age: 55
Executive Vice-President of Finance & Strategy
Chief Executive Officer of LFB Hemoderivados E Biotecnologia Ltda, Brazil
Sales Director and Executive Vice-President of Global Marketing & Sales - Lfb Biomedicaments Sa
Managing Director of Europlasma AT GmbH
Compensation as of Fiscal Year 2015.

LFB S.A. Key Developments

Knight Therapeutics Inc. and LFB S.A. Announce Filing Of New Drug Submission for Atryn(r)

Knight Therapeutics Inc. and LFB S.A. announced that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for ATryn(r) [Antithrombin (Recombinant)] for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

The LFB Group Announces Financial Results for the Financial Year Ended 31 December 2014

The LFB Group announced financial results for the financial year ended 31 December 2014. For the year, the company reported sales revenue of €501.9 million against €477.2 million a year ago. Net result was €13 million against €8.2 million a year ago. Net debt was down from €45.4 million at the end of 2013 to €41.3 million at the end of 2014. Due to elements and to the reversals of provisions allowed by a normalization of the commercial situation in Brazil, the group operating profit reached €25.2 million against €19.8 million in 2013.

LFB SA Begins First Patient Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors

LFB SA, through its U.S. subsidiary, announced that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors. This Phase 3 clinical trial is a global open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes and should be completed in 2015. The start of patient treatment is an important milestone in the development of LR769 for hemophilia A and B patients with inhibitors to Factor VIII or IX. Based on promising data from earlier studies, the company believes that LR769 has the potential to be a significant advance for people with hemophilia, and it will fully explore its potential as the first new therapeutic option in more than 15 years. Additional Phase 3 studies will assess the efficacy of LR769 for the treatment of bleeding episodes in pediatric hemophilia patients with inhibitors and will evaluate the prevention of bleeding complications in patients undergoing surgery. These studies are expected to start in early 2015.

Similar Private Companies By Industry

Company Name Region
Eco Process Energie Environnement Europe
Cybergene SA Europe
BioFilm Control SAS Europe
Antagene Europe
SeleXel Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LFB S.A., please visit www.lfb.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.